Trachoma Treatment Market Expected to Reach $924.43 Million by 2032, Growing at a CAGR of 6.8%

Market Overview:

The global trachoma treatment market size is expected to reach USD 924.43 million by 2032,  exhibiting a CAGR of 6.8% during the forecast period.

The growing cases of trachoma, particularly in nations of Asia and the Middle East nations, and the escalation in aggregate of public consciousness crusades and ingenuity renders people conscious of the indicators, nursing alternatives, and prohibition of trachoma. These factors are pushing towards market expansion. Moreover, funding in the healthcare sector is proliferating speedily in advancing nations such as South Korea, India, China, and Malaysia. This causes an escalated outpouring of progressive healthcare solutions and favors involving premature diagnosis and cure of trachoma, pushing the market growth.

Trachoma is a bacterial contamination that influences the eyes. It is transmissible unfurling through proximity with eyes, eyelids, nose, or throat emissions of contaminated people. It can also be spread by managing contaminated items such as handkerchiefs. In the premature phases of trachoma cure with antibiotics by itself may not be sufficient to eradicate infections. The doctor may advise tetracycline eye ointment or oral azithromycin. The World Health Organization (WHO) endorses administering antibiotics to the whole community when an additional 10% of children have been impacted by trachoma.

Download Free Sample PDF Copy of the Report:

https://www.polarismarketresearch.com/industry-analysis/trachoma-treatment-market/request-for-sample

Company Profiles

The trachoma treatment industry leaders are:

• Abbott Laboratories
• AbbVie Inc.
• Allergan Inc.
• Arbor Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Bayer AG.
• Cipla Inc
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sanofi SA

Key Takeaways from the Report

• The primary factors propelling the market growth of trachoma treatment are the growing pervasiveness of trachoma and consciousness about disease prohibition.

• The trachoma treatment market analysis is dependent on the route of administration, drug class, and region.

• In 2023, North America dominated the market.

• The market in Asia Pacific will increase as a result of factors such as governments and healthcare firms concentrating on extensive treatment procedures involving antibiotics and surgeries.

Country-Wise Insights:

Trachoma Treatment Market, Regional Outlook (Revenue – USD Million, 2019-2032)

• North America
  • Route of Administration Outlook
    • Oral
    • Topical
  • Drug Class Outlook
    • Macrolides
    • Tetracycline
    • Ophthalmic Anti-infective
    • Sulfonamides
• Europe
  • Route of Administration Outlook
    • Oral
    • Topical
  • Drug Class Outlook
    • Macrolides
    • Tetracycline
    • Ophthalmic Anti-infective
    • Sulfonamides

Recent Developments in the Industry

• July 2023 – Vision Spring, Live Well, and the Council of Churches Zambia:
  These organizations officially launched a new vision correction program in Zambia, targeting a significant portion of the population. The program aims to provide treatment for conditions such as cataracts and trachoma, with expectations that 75% of participants will require some form of vision correction.
• June 2022 – Pfizer Inc.:
  Pfizer announced the extension of its donation program for the antibiotic Zithromax until 2030. The drug is used in the fight against trachoma, a leading infectious cause of blindness. This extension reinforces Pfizer’s ongoing commitment to supporting global efforts to eliminate trachoma.

The rapid increase in the prevalence of trachoma and its proliferation among private and public healthcare organizations to raise awareness about trachoma and its treatment options among the general public are prominent factors driving the market growth.